AI assistant
Sending…
Immunome Inc. — Director's Dealing 2020
Nov 6, 2020
32238_dirs_2020-11-05_a9047499-fb08-46ad-86e8-ffa58b23b894.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-11-03
Reporting Person: RAPP MICHAEL (Director, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-11-03 | Stock Option (Right to Buy) | $11.38 | A | 7500 | Acquired | 2030-11-03 | Common Stock (7500) | Direct |
Footnotes
F1: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter.
More from Immunome Inc.
Annual Report
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 3
Regulatory Filings
2026
Mar 3
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2025
Dec 31
Director's Dealing
2025
Dec 23
Major Shareholding Notification
2025
Dec 23